This company has been acquired
Amryt Pharma (AMYT) Stock Overview
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AMYT from our risk checks.
AMYT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Amryt Pharma plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.70 |
| 52 Week High | US$14.77 |
| 52 Week Low | US$6.41 |
| Beta | 0.75 |
| 1 Month Change | 0.96% |
| 3 Month Change | -0.14% |
| 1 Year Change | 86.55% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 84.91% |
Recent News & Updates
Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU
Oct 18Amryt growth hormone disorder drug Mycapssa gets EMA panel nod for EU approval
Sep 16Amryt gets British marketing approval & orphan drug designation for rare skin disease gel
Sep 08Amryt stock rises 11% on FDA orphan drug status for Mycapssa for rare tumor condition
Jul 14Amryt's Filsuvez gets approval in EU to treat rare skin disorder
Jun 23Recent updates
Shareholder Returns
| AMYT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.7% | -0.5% | 3.0% |
| 1Y | 86.5% | 37.6% | 25.7% |
Return vs Industry: AMYT exceeded the US Pharmaceuticals industry which returned -3.7% over the past year.
Return vs Market: AMYT exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| AMYT volatility | |
|---|---|
| AMYT Average Weekly Movement | 0.4% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: AMYT's share price has been volatile over the past 3 months.
Volatility Over Time: AMYT's weekly volatility has decreased from 16% to 0% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 289 | Joe Wiley | www.amrytpharma.com |
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB.
Amryt Pharma plc Fundamentals Summary
| AMYT fundamental statistics | |
|---|---|
| Market cap | US$940.67m |
| Earnings (TTM) | -US$790.00k |
| Revenue (TTM) | US$243.62m |
Is AMYT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AMYT income statement (TTM) | |
|---|---|
| Revenue | US$243.62m |
| Cost of Revenue | US$111.31m |
| Gross Profit | US$132.32m |
| Other Expenses | US$133.11m |
| Earnings | -US$790.00k |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 54.31% |
| Net Profit Margin | -0.32% |
| Debt/Equity Ratio | 64.3% |
How did AMYT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/14 13:59 |
| End of Day Share Price | 2023/04/11 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Amryt Pharma plc is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michelle Gilson | Canaccord Genuity |
| Brandon Folkes | Cantor Fitzgerald & Co. |
| Andrew Young | Davy |